$ 49 / 10mg
999 in stock (can be backordered)
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that targets the ghrelin receptor (GHS-R1a) to stimulate rapid, controlled growth-hormone release from the anterior pituitary. Distinguished from other GH secretagogues by its strong appetite-stimulating properties, GHRP-6 peptide is a valuable research tool for studying the intersection of GH signaling, ghrelin-mediated hunger pathways, and metabolic regulation.
GHRP-6 peptide activates GHS-R1a receptors, triggering both GH secretion and ghrelin-like appetite signaling. This dual activity makes it uniquely useful for research examining the relationship between growth-hormone pulses and feeding behavior. In preclinical models, GHRP-6 produces robust GH elevation alongside significant increases in food intake — a pharmacological profile distinct from more selective secretagogues like Ipamorelin.
GHRP-2 offers stronger GH release with less appetite stimulation for comparison studies. Hexarelin provides the highest GH potency in the GHRP family. For dual-pathway research, pairing with CJC-1295 (No DAC) combines GHRP and GHRH receptor activation.
Each vial contains GHRP-6 peptide manufactured in the USA under ISO-certified conditions. Verified to ≥99% purity by HPLC analysis, with endotoxin screening below 0.1 EU/mg. Certificate of Analysis (COA) available upon request. For laboratory research use only.
GHRP-6 is supplied as a lyophilized (freeze-dried) powder to ensure maximum peptide stability during storage and transport. Store unopened vials at -20°C in a dry, light-protected environment. Reconstitute with bacteriostatic water using sterile aseptic technique prior to experimental use. After reconstitution, store the peptide solution at 2–8°C (standard laboratory refrigerator) and use within 28 days to preserve hexapeptide integrity and GHS-R1a binding activity. Avoid repeated freeze-thaw cycles, as thermal stress can degrade the six-amino-acid sequence. Handle with appropriate laboratory PPE. For research use only.
GHRP-6 was first synthesized in the early 1980s by Cyril Bowers and colleagues at Tulane University as part of pioneering work on growth-hormone-releasing peptides. It was among the first synthetic compounds demonstrated to stimulate GH release through the then-unknown ghrelin receptor, which was subsequently identified as GHS-R1a in 1996 by Howard et al. GHRP-6 has since been the subject of more than 200 peer-reviewed publications in journals including Endocrinology, the Journal of Clinical Endocrinology & Metabolism, and Neuroendocrinology. Research groups at Tulane University, the University of Virginia, and institutions across Europe and Japan have characterized its pharmacology, appetite-stimulating properties, and gastroprotective effects in preclinical models. Its role in the discovery of the ghrelin signaling pathway makes it one of the most historically significant peptides in endocrinology research. This compound is sold for laboratory research use only.
GHRP-6 is a synthetic hexapeptide that stimulates growth-hormone release via the ghrelin receptor. Its distinguishing feature is strong appetite stimulation alongside GH release, making it valuable for research examining the intersection of growth-hormone and hunger signaling pathways.
GHRP-6 produces robust GH release with significant appetite stimulation. GHRP-2 offers stronger GH pulses with less hunger effect, while Ipamorelin is the most selective with minimal cortisol or appetite impact. Each serves different research objectives.
USA-manufactured under ISO-certified conditions, ≥99% HPLC-verified purity, endotoxin levels below 0.1 EU/mg. COA available upon request. For laboratory research use only.
